HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

UPC

Universe Pharmaceuticals INC (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

None
$4.01
$-0.24 (-5.65%)
Sign in to add UPC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$3.53M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-8.06
Dividend Yield-
Profit Margin-20.56%
Revenue Growth-14.10%
ROE-7.23%
Debt/Equity16.49
Recommendation None
Analyst Target-
Analysts-
Indexes NASDAQ

Technical Indicators

RSI (14)56.0
Beta1.60
SMA 20-
SMA 40-
52-Week High$17.96
52-Week Low$2.00
50-Day Avg$3.33
200-Day Avg$3.74
Avg Volume$1.47M
Volume34.2K

Performance Analysis

NEUTRAL

UPC presents a mixed picture with both positive and negative indicators.

~ Trading at 13% of its 52-week range.
+ RSI at 56.0 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 14.1% year-over-year.
- Operating at a loss with -20.6% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:36 UTC

Back to Screener Export Report